Comprehensive Monograph on Berzosertib (DB11794): An Investigational First-in-Class ATR Kinase Inhibitor

Executive Summary

Berzosertib is a first-in-class, potent, and selective intravenous inhibitor of the Ataxia telangiectasia and Rad3-related (ATR) kinase. As a pioneer in its therapeutic class, it has been instrumental in validating the strategy of targeting the DNA Damage Response (DDR) in oncology. Its clinical development has yielded a dichotomous narrative: demonstrating significant, practice-informing efficacy in specific, biomarker-enriched populations such as platinum-resistant ovarian cancer, while simultaneously failing to meet endpoints in broader, less-selected patient groups, exemplified by the discontinuation of a pivotal trial in small cell lung cancer (SCLC).

The primary mechanism of action for Berzosertib involves the blockade of the ATR-Checkpoint Kinase 1 (Chk1) signaling pathway, a critical cell cycle checkpoint activated by replication stress. This inhibition prevents cancer cells from repairing damaged DNA, leading to mitotic catastrophe and apoptosis. This therapeutic strategy is based on the principle of synthetic lethality, which is particularly effective in tumors with pre-existing DDR defects, such as those with Ataxia-telangiectasia mutated (ATM) or TP53 mutations.

The most compelling clinical evidence for Berzosertib's efficacy comes from the randomized Phase II trial NCT02595892 in platinum-resistant ovarian cancer. In this study, the addition of Berzosertib to gemcitabine significantly improved progression-free survival compared to gemcitabine alone. Conversely, the global Phase II DDRiver SCLC 250 trial in platinum-resistant SCLC was discontinued for futility, a major setback that underscores the critical importance of patient selection for this class of agents.

The primary and dose-limiting toxicity of Berzosertib, particularly when used in combination with cytotoxic chemotherapy, is myelosuppression, manifesting as anemia, thrombocytopenia, and neutropenia. This hematologic toxicity is a direct on-target effect of ATR inhibition in rapidly dividing hematopoietic progenitor cells and represents the main challenge in achieving a wide therapeutic index.

The future of Berzosertib is contingent on a biomarker-driven development strategy. Its path forward lies not in broad applications but in precision oncology, targeting tumors with validated signatures of DDR deficiency or high replication stress. Ongoing trials with novel combination partners, such as the DNA-damaging agent lurbinectedin and the antibody-drug conjugate sacituzumab govitecan, will be crucial in determining its ultimate place in the therapeutic armamentarium. Its legacy as a foundational ATR inhibitor continues to inform the development of next-generation oral agents in this promising class.

Introduction to Berzosertib: An Investigational ATR Kinase Inhibitor

Berzosertib represents a pioneering effort in the clinical application of DNA Damage Response (DDR) inhibition, specifically targeting the ATR kinase. Its journey from an early-stage asset to a widely studied investigational agent reflects the growing interest in exploiting the inherent genomic instability of cancer cells as a therapeutic vulnerability.

Developmental Trajectory and Commercial Rights

Berzosertib was originally invented and developed by Vertex Pharmaceuticals under the development codes VE-822 and VX-970.[1] It emerged from research programs aimed at identifying potent and selective inhibitors of the phosphoinositide 3-kinase-related kinase (PIKK) family. In 2017, the development and commercial rights for the compound were licensed to Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada.[1] Under Merck KGaA, the drug was assigned the development code M6620 and became the lead candidate in the company's DDR inhibitor portfolio.[3] This transition from a biotechnology innovator to a major global pharmaceutical company signified a strong belief in the therapeutic potential of the ATR inhibitor class and the broader DDR field. Berzosertib holds the distinction of being the first ATR inhibitor to be evaluated in a randomized clinical trial, establishing a clinical precedent for this mechanism of action.[3]

Chemical and Physical Properties

Berzosertib is a synthetic organic small molecule designed for therapeutic use.[7] Its fundamental properties are well-characterized and serve as the basis for its pharmacological activity. The molecule is classified chemically as a sulfonamide and belongs to the class of organic compounds known as benzenesulfonyl compounds, which are defined by an aromatic structure containing a benzene ring that carries a sulfonyl group.[7] Key identifiers and physicochemical properties are summarized in Table 1.

Identifier/Property	Value	Source Snippets
Generic Name	Berzosertib	7
DrugBank ID	DB11794	1
CAS Number	1232416-25-9	1
Development Codes	VX-970, VE-822, M6620	1
Drug Type	Small Molecule	7
IUPAC Name	3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine	1
Chemical Formula	C24​H25​N5​O3​S	1
Average Molecular Weight	463.56 g·mol⁻¹	1
Canonical SMILES	CNCc1ccc(cc1)c1noc(c1)c1nc(cnc1N)c1ccc(cc1)S(=O)(=O)C(C)C	8
InChIKey	JZCWLJDSIRUGIN-UHFFFAOYSA-N	1
Lipinski's Rule of Five	Yes (0 rules broken)	7
Veber's Rule	No	7

Regulatory Landscape

As an investigational agent, Berzosertib has not been approved for any clinical use by regulatory authorities in any jurisdiction.[3] It is currently in Phase II clinical development for the treatment of various solid tumors.[11]

The drug's regulatory history includes a notable designation from the European Medicines Agency (EMA). Berzosertib was granted a rare disease (orphan) designation for the "Treatment of small cell lung cancer".[10] This status is conferred to encourage the development of medicines for rare, life-threatening, or chronically debilitating conditions where a significant benefit over existing therapies is plausible.[12] However, this designation was officially withdrawn on July 18, 2022.[10] This regulatory event was not an isolated administrative decision but a direct consequence of the clinical trial data emerging at the time. The withdrawal followed shortly after the discontinuation of the pivotal Phase II DDRiver SCLC 250 trial in June 2022, which was stopped after an interim analysis revealed a low probability of success.[5] The failure of this key trial removed the evidence base supporting the potential for "significant benefit" required to maintain the orphan designation, demonstrating a clear cause-and-effect relationship between clinical outcomes and regulatory standing. No specific orphan drug designation from the U.S. Food and Drug Administration (FDA) has been noted.[17]

Pharmacodynamics: Mechanism of Action and Preclinical Rationale

The therapeutic hypothesis for Berzosertib is rooted in the fundamental biology of the DNA Damage Response, a complex network of cellular pathways that sense, signal, and repair DNA lesions to maintain genomic integrity. Berzosertib targets a central node in this network, the ATR kinase, to exploit the unique dependencies of cancer cells.

The ATR-Chk1 Pathway: A Guardian of Genomic Integrity

The Ataxia telangiectasia and Rad3-related (ATR) protein is a master regulator and apical kinase within the DDR network.[10] While other key DDR kinases like ATM and DNA-dependent protein kinase (DNA-PK) primarily respond to DNA double-strand breaks (DSBs), ATR is activated by a wider spectrum of DNA damage, most critically by the presence of extensive regions of single-stranded DNA (ssDNA).[21] Such ssDNA structures are a common feature of replication stress, a state where the DNA replication machinery encounters obstacles, leading to the stalling or collapse of replication forks.[22]

Replication stress is a constitutive feature of many cancers. It is often driven by the expression of oncogenes (e.g., MYC, CCNE1) that promote uncontrolled cell proliferation, overwhelming the normal replication process.[22] To survive this constant endogenous stress, cancer cells become highly dependent on the ATR pathway. Upon sensing ssDNA coated by Replication Protein A (RPA), ATR is recruited and activated. It then phosphorylates a vast array of downstream substrates, with Checkpoint Kinase 1 (Chk1) being one of the most critical.[10] The activated ATR-Chk1 signaling cascade initiates a comprehensive cellular response that includes:

1. Activation of Cell Cycle Checkpoints: The pathway halts cell cycle progression, primarily at the intra-S and G2/M phases, to prevent cells from entering mitosis with damaged or incompletely replicated DNA.[19]
2. Stabilization of Stalled Replication Forks: It protects the stalled replication machinery from collapsing into lethal DSBs, allowing for potential restart of DNA synthesis.[22]
3. Promotion of DNA Repair: The pathway facilitates the recruitment and activation of various DNA repair factors to the sites of damage.[26]

This protective function is particularly vital for cancer cells, which frequently harbor defects in other checkpoint pathways, such as the G1 checkpoint controlled by p53.[22]

Molecular Inhibition by Berzosertib

Berzosertib is a highly potent and selective ATP-competitive inhibitor of ATR kinase activity.[1] Preclinical characterization has demonstrated a high affinity for its target, with a dissociation constant (

Ki​) of less than 0.3 nM and a half-maximal inhibitory concentration (IC50​) of approximately 19 nM in cellular assays.[20] Its selectivity is a key feature; it is over 1000-fold more selective for ATR than for DNA-PK and maintains significant selectivity over the closely related ATM kinase (

Ki​ = 34 nM).[20]

By binding to the kinase domain of ATR, Berzosertib prevents the phosphorylation and subsequent activation of Chk1 and other downstream substrates, effectively shutting down the ATR-mediated signaling cascade.[10] The functional consequence of this molecular inhibition is the abrogation of the DNA damage checkpoint. In the presence of DNA damage (either endogenous or therapy-induced), cells treated with Berzosertib are unable to arrest the cell cycle to perform repairs. They are forced to progress into mitosis with damaged DNA, an event that leads to replication fork collapse, the accumulation of catastrophic DSBs, widespread chromosomal abnormalities, and ultimately, apoptotic cell death.[10]

The Principle of Synthetic Lethality: Exploiting Cancer's Achilles' Heel

The central therapeutic strategy underpinning Berzosertib is the concept of synthetic lethality. This principle describes a situation where the loss of function in either of two genes individually is viable, but the simultaneous loss of both is lethal.[22] In the context of Berzosertib, the targeted inhibition of ATR is synthetically lethal with pre-existing defects in other DDR pathways commonly found in cancer cells.

Many tumors exhibit a defective G1 cell cycle checkpoint due to mutations in key tumor suppressor genes like TP53 or ATM. This loss of the primary "gatekeeper" checkpoint makes these cancer cells critically dependent on the ATR-governed intra-S and G2/M checkpoints to manage replication stress and repair DNA damage before cell division.[20] By administering Berzosertib, this remaining essential checkpoint is disabled. The cancer cell, now lacking any functional mechanism to pause and repair, accumulates lethal levels of genomic damage and is selectively eliminated. In contrast, normal, healthy cells typically have an intact G1 checkpoint and lower levels of replication stress, making them less sensitive to the effects of ATR inhibition.[20] This differential dependency creates a therapeutic window. This biological rationale is strongly supported by preclinical findings that demonstrated that defects in the ATM-p53 pathway were predictive of tumor cell sensitivity to Berzosertib.[20]

Preclinical Evidence as a Chemo- and Radiosensitizing Agent

While Berzosertib has shown some single-agent activity in tumor models with high intrinsic replication stress and DDR defects, its primary therapeutic potential lies in its ability to act as a powerful sensitizing agent, augmenting the efficacy of conventional DNA-damaging cancer therapies.[20]

• Chemosensitization: Extensive preclinical research has shown that Berzosertib markedly enhances the cytotoxicity of a wide range of chemotherapeutic agents. These agents create the very DNA lesions that activate the ATR pathway, making the cancer cells acutely vulnerable to ATR inhibition. Demonstrated synergies include:
• Platinum Agents: Cisplatin and Carboplatin, which form DNA adducts and crosslinks.[20]
• Topoisomerase Inhibitors: Topotecan and Irinotecan, which cause replication-associated DNA breaks.[20]
• Antimetabolites: Gemcitabine, which disrupts DNA synthesis.[2]
• Radiosensitization: Berzosertib is also a potent radiosensitizer. Ionizing radiation induces a variety of DNA lesions, including DSBs, which trigger a DDR. By inhibiting ATR, Berzosertib prevents the repair of this radiation-induced damage, leading to enhanced tumor cell killing.[2] This effect has been observed in preclinical models of non-small cell lung cancer brain metastases, suggesting a potential role in this challenging clinical setting.[20]
• Combination with PARP Inhibitors: Strong synergistic activity has been documented when Berzosertib is combined with PARP inhibitors. This combination creates a powerful synthetic lethal interaction by simultaneously blocking two critical arms of the DDR pathway, leading to profound antitumor effects in preclinical models.[20]

The mechanism of Berzosertib provides a clear and direct explanation for its most significant clinical toxicity. The ATR pathway is not a cancer-specific process but a fundamental biological mechanism essential for the viability of any cell population undergoing rapid replication. The most prominent example of such a population in the human body is the hematopoietic progenitor cells located in the bone marrow. These cells are in a constant state of proliferation to replenish the body's supply of blood cells and, consequently, experience high levels of intrinsic replication stress. Their survival is highly dependent on a functional ATR pathway to maintain genomic stability during this rapid division. When a systemic ATR inhibitor like Berzosertib is administered, it inevitably affects these healthy, rapidly dividing bone marrow cells in the same way it affects cancer cells. This leads directly to the severe myelosuppression—anemia, thrombocytopenia, and neutropenia—that is consistently observed as the dose-limiting toxicity in clinical trials.[35] This hematologic toxicity is therefore not an off-target or unexpected side effect but a direct, on-target consequence of the drug's fundamental mechanism of action. This reality establishes a narrow therapeutic window between achieving an effective antitumor concentration and causing unacceptable damage to essential healthy tissues.

Pharmacokinetic Profile: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic (PK) profile of Berzosertib, which describes how the body absorbs, distributes, metabolizes, and excretes the drug, has been characterized through a series of preclinical and clinical studies. These studies provide a comprehensive understanding of its disposition and have informed its clinical development and dosing schedules.

Administration and Pharmacokinetic Model

Berzosertib is formulated for intravenous (IV) administration and is typically delivered as an infusion.[20] A population pharmacokinetic (PopPK) analysis, which integrated data from 240 patients with advanced cancers across two Phase I studies (NCT02157792 and EudraCT 2013-005100-34), provided a robust model of its behavior in humans. The analysis concluded that the pharmacokinetics of Berzosertib are best described by a two-compartment linear model over the evaluated dose range of 18–480 mg/m².[38] For a typical patient, the estimated clearance (CL) was 65 L/h. The terminal elimination half-life (

t1/2​) of the parent drug is approximately 17 to 19.6 hours.[38]

Distribution

The PopPK model revealed a large volume of distribution, with an estimated central volume of distribution (Vc​) of 118 L and a peripheral volume of distribution (Vp​) of 1030 L. The intercompartmental clearance, describing the rate of transfer between the central and peripheral compartments, was estimated at 295 L/h.[38] This large volume of distribution indicates that Berzosertib distributes extensively from the plasma into peripheral tissues. This is consistent with preclinical studies in mice, which showed extensive distribution into key tissues such as bone marrow, tumor, thymus, and lymph nodes.[41]

A key aspect of Berzosertib's PK is its nonlinear behavior, which is attributed to the saturation of plasma protein binding. This phenomenon occurs at concentrations that are achieved in clinical trials.[41] At lower doses, a larger fraction of the drug is bound to plasma proteins, limiting its distribution. As the dose increases and binding sites become saturated, the proportion of free, unbound drug in the plasma increases. This leads to less than proportional increases in early plasma concentrations but greater than proportional increases in tissue exposure, as more free drug is available to diffuse into tissues.[41]

Metabolism

Metabolism is the primary mechanism of clearance for Berzosertib. A human mass balance study using radiolabeled [¹⁴C]berzosertib demonstrated that the drug undergoes extensive metabolic transformation.[40] This is supported by the finding that circulating metabolites account for a substantial portion (78%) of the total drug-related material in plasma.[40] Furthermore, the terminal half-life of total radioactivity in plasma (64.3 hours) is significantly longer than that of the unchanged parent drug (19.6 hours), indicating the presence of metabolites that are eliminated more slowly than Berzosertib itself.[40]

In vitro studies have identified the cytochrome P450 enzyme CYP3A4 as the primary mediator of Berzosertib's metabolism.[38] The major circulating metabolite has been identified as

M11. This metabolite is considered pharmacologically inactive and is the most abundant metabolic product found in plasma, accounting for 28.2% of the total drug-related material based on peak concentration and 43.5% based on total exposure (AUC).[40]

Excretion

The definitive routes of excretion for Berzosertib and its metabolites were established in the human [¹⁴C]berzosertib mass balance study.[40] Over a 14-day collection period, a mean total recovery of 89.5% of the administered radioactive dose was achieved. The data clearly show that elimination occurs predominantly through the hepatobiliary system.

• Fecal Excretion: This is the primary route of elimination, accounting for a mean of 73.7% of the administered dose.
• Urinary Excretion: This is a secondary route, accounting for a mean of 15.8% of the dose.

These findings confirm that direct renal excretion of the unchanged parent drug is a minor pathway of elimination (estimated at only 5–6%).[38] The overall disposition of Berzosertib involves extensive CYP3A4-mediated metabolism followed by the excretion of metabolites primarily into the feces.

Special Considerations: The Blood-Brain Barrier (BBB) Challenge

While early preclinical data suggested that Berzosertib had good potential for penetrating the blood-brain barrier [20], this created a degree of optimism for its use in treating brain metastases and primary brain tumors like glioblastoma (GBM). However, subsequent, more detailed preclinical investigations using patient-derived xenograft models of GBM revealed significant obstacles to achieving therapeutic concentrations in the central nervous system.[43] These studies identified a critical disconnect between the initial promise and the clinical reality of treating CNS tumors.

The primary challenges are twofold. First, Berzosertib is a substrate for active efflux transporters at the BBB, which actively pump the drug out of the brain and back into the bloodstream, severely restricting its net accumulation.[43] Second, the drug exhibits a high degree of binding to brain tissue relative to plasma. This high tissue binding sequesters the drug, leading to very low concentrations of the free, unbound fraction that is pharmacologically active and available to interact with its target.[43] This explains why the potent synergy observed between Berzosertib and the chemotherapy temozolomide in vitro could not be recapitulated in in vivo GBM models. The distribution within intracranial tumors was also found to be heterogeneous; while some drug accumulated in the leaky tumor core, concentrations were sub-therapeutic in the invasive tumor rim and surrounding brain tissue, where the BBB remains intact and where tumor recurrence originates.[43] This is a classic challenge in CNS drug development, where it is not sufficient for a drug to simply cross the BBB; it must achieve and sustain adequate concentrations of its free, active form at the site of action. These pharmacokinetic findings strongly suggest that without novel delivery strategies, the utility of systemically administered Berzosertib for primary brain tumors is likely to be limited, a crucial consideration for future clinical trial design.

Clinical Development and Efficacy Analysis

The clinical development program for Berzosertib has been extensive, exploring its potential across a wide range of malignancies and in combination with numerous standard-of-care agents. This broad investigation has produced a complex and informative set of results, with notable successes in specific contexts and significant setbacks in others, collectively shaping the current understanding of where ATR inhibition may fit into cancer therapy.

Overview of the Clinical Trial Program

Berzosertib has been evaluated in at least 21 clinical trials, primarily Phase I, I/II, and II studies.[30] The program has investigated Berzosertib both as a monotherapy and, more prominently, as a chemosensitizing or radiosensitizing agent.[7] The most frequently studied indications include malignant solid tumors, small cell lung carcinoma (SCLC), and non-small cell lung carcinoma (NSCLC).[7] A key feature of many of these trials, particularly in later stages, has been the inclusion of biomarker criteria for patient selection, with a focus on tumors harboring alterations in DDR pathway genes such as

ATM and ATR.[30]

Efficacy in Gynecologic Malignancies (Primarily Ovarian Cancer)

The most compelling evidence for the clinical efficacy of Berzosertib has emerged from studies in gynecologic cancers, particularly platinum-resistant high-grade serous ovarian cancer.

• NCT02595892 (Randomized Phase II): This multicenter, randomized trial is the landmark study for the Berzosertib program.[1] It was designed to test the hypothesis that adding Berzosertib to standard-of-care gemcitabine would improve outcomes for patients with platinum-resistant disease.
• Progression-Free Survival (PFS): The trial successfully met its primary endpoint. The combination of Berzosertib and gemcitabine resulted in a statistically significant improvement in median PFS compared to gemcitabine alone (22.9 weeks vs. 14.7 weeks; Hazard Ratio 0.57; p=0.044).[1] The clinical benefit was even more pronounced in the subset of patients with the most platinum-resistant tumors (those who had progressed within 3 months of their last platinum therapy).[50]
• Overall Survival (OS) and Biomarker Analyses: The final analysis of the secondary endpoint, overall survival, did not show a statistically significant benefit in the intent-to-treat (ITT) population (median OS 59.4 weeks vs. 43.0 weeks; HR 0.79; p=0.18). However, this result was significantly confounded by the fact that 15 patients (42%) in the control arm crossed over to receive the Berzosertib combination upon progression.[48] Post-hoc exploratory analyses that adjusted for this crossover suggested a significant OS benefit. Furthermore, pre-planned biomarker analyses revealed that the survival benefit was most pronounced in specific patient subgroups, including those with a platinum-free interval of ≤3 months and those whose tumors were ATM-negative/low by immunohistochemistry or were classified as having a low replication stress (RS-low) genomic signature.[48] These findings strongly support a biomarker-driven approach for patient selection.

Application in Small Cell Lung Cancer (SCLC)

The investigation of Berzosertib in SCLC has been a story of initial promise followed by a significant setback.

• NCT02487095 (NCI-led Phase I/II): This proof-of-concept study generated considerable excitement by combining Berzosertib with the topoisomerase inhibitor topotecan for relapsed SCLC.[6] The trial reported a confirmed objective response rate (ORR) of 36%, with durable responses lasting a median of 6.4 months.[6] This was a remarkable result, given that responses were observed in both platinum-sensitive (60% ORR) and platinum-resistant (30% ORR) cohorts, the latter of which has a historical response rate to topotecan alone of only around 5%.[56]
• DDRiver SCLC 250 (Global Phase II, NCT04768296): Based on the highly encouraging data from the NCI trial, Merck KGaA launched this larger, global Phase II study to confirm the efficacy of the Berzosertib-topotecan combination in patients with relapsed, platinum-resistant SCLC.[3] However, in June 2022, the company announced the discontinuation of the trial. The decision was based on a planned interim analysis which concluded that there was a "low probability of success" in meeting the study's pre-defined primary objective.[4] This failure to replicate the early promise in a larger setting was a major blow to the Berzosertib program and tempered enthusiasm for its broad application in SCLC.

Investigations in Other Solid Tumors

The efficacy of Berzosertib has been variable across other solid tumor types, further reinforcing the need for patient stratification.

• Metastatic Urothelial Carcinoma: A randomized Phase II trial that added Berzosertib to a standard cisplatin and gemcitabine backbone failed to demonstrate any benefit.[37] Median PFS was identical in both arms (8.0 months), and a concerning trend toward inferior OS was observed in the Berzosertib arm. This negative result was likely driven by the increased hematologic toxicity of the triplet combination, which necessitated significant dose reductions of the cisplatin backbone, thereby compromising its efficacy.[37]
• ATM-Mutant Tumors: In contrast, a Phase I trial (NCT02595931) combining Berzosertib with irinotecan provided strong clinical validation for the synthetic lethality hypothesis.[33] While modest activity was seen overall, striking and durable partial responses were observed specifically in patients with pancreatic cancer whose tumors harbored ATM alterations. One such response lasted for over 15 months, providing a clear signal of efficacy in this molecularly defined subgroup.[33]
• Triple-Negative Breast Cancer (TNBC): An expansion cohort of the NCT02157792 trial evaluated Berzosertib with cisplatin in patients with advanced, germline BRCA-wildtype TNBC. The combination was found to be tolerable and produced an ORR of 23.4%.[31]
• Early Phase Solid Tumor Trials: Initial Phase I dose-escalation studies of Berzosertib, both as a monotherapy and in combination with carboplatin or cisplatin, established its safety and recommended Phase II doses. These early trials also showed preliminary signs of antitumor activity, including durable responses in heavily pre-treated patients with various advanced solid tumors.[1]

Ongoing Trials of Interest

The clinical development of Berzosertib continues, with a strategic focus on novel, rational combinations in biomarker-selected populations. Two active trials are particularly noteworthy:

• NCT04802174: A Phase I/II study investigating Berzosertib in combination with lurbinectedin, a selective inhibitor of oncogenic transcription, in SCLC and other high-grade neuroendocrine cancers.[45]
• NCT04826341: A Phase I/II study combining Berzosertib with sacituzumab govitecan, an antibody-drug conjugate that delivers a topoisomerase I inhibitor payload. This trial is enrolling patients with SCLC and other solid tumors characterized by homologous recombination deficiency (HRD) that are resistant to PARP inhibitors.[45]

The clinical journey of Berzosertib provides a powerful illustration of the evolution from a broad, histology-based approach to a more refined, precision medicine strategy. The initial hypothesis—that adding an ATR inhibitor to chemotherapy would be broadly effective in cancers with high replication stress—proved to be overly simplistic. This approach led to clear failures, as seen in the urothelial cancer trial where increased toxicity negated any potential benefit, and in the unselected SCLC population of the pivotal DDRiver trial.[5] In parallel, clear successes emerged in specific, biologically defined contexts: platinum-resistant ovarian cancer, a disease state known for its DDR vulnerabilities, and most compellingly, in tumors with confirmed

ATM mutations.[33] This pattern of results strongly argues that the therapeutic value of Berzosertib is not universal but is unlocked by specific molecular vulnerabilities. The failure in the large SCLC trial may not have been a failure of the drug's mechanism, but rather a failure of the patient selection strategy. Consequently, the future of Berzosertib and the entire ATR inhibitor class depends on moving away from histology-driven trials and toward biomarker-selected "basket" trials that enroll patients based on molecular profiles. The ongoing trials with novel partners in HRD-positive tumors reflect this necessary strategic evolution.[46]

Trial ID	Phase	Cancer Type(s)	Combination Agent(s)	Primary Endpoint(s)	Key Findings / Status	Source Snippets
NCT02595892	II	Platinum-Resistant Ovarian Cancer	Gemcitabine	Progression-Free Survival (PFS)	Positive: Met primary endpoint. Median PFS 22.9 vs 14.7 weeks (HR 0.57). OS benefit in biomarker-selected subgroups.	1
DDRiver SCLC 250 (NCT04768296)	II	Platinum-Resistant SCLC	Topotecan	Objective Response Rate (ORR)	Negative: Discontinued due to low probability of success at interim analysis.	3
NCT02487095	I/II	SCLC & Extrapulmonary Small Cell Cancers	Topotecan	MTD (Ph I), ORR (Ph II)	Positive (PoC): Showed promising ORR of 36% and durable responses, providing rationale for DDRiver 250.	6
JAMA Oncology Trial (Pal et al.)	II	Metastatic Urothelial Carcinoma	Cisplatin + Gemcitabine	PFS	Negative: No improvement in PFS (8.0 vs 8.0 mos). Trend toward inferior OS. Higher toxicity.	37
NCT02595931	I	Advanced Solid Tumors	Irinotecan	MTD, RP2D	Positive Signal: Manageable safety. Promising activity in ATM-mutant tumors (pancreatic cancer).	33
NCT02157792	I	Advanced Solid Tumors (incl. TNBC)	Monotherapy, Carboplatin, Cisplatin	Safety, MTD, RP2D	Positive (Early Phase): Well tolerated. Preliminary antitumor activity observed. RP2D established.	31
NCT04802174	I/II	SCLC, HGNEC	Lurbinectedin	MTD (Ph I), ORR (Ph II)	Ongoing: Actively recruiting.	45
NCT04826341	I/II	SCLC, HRD+ Cancers	Sacituzumab Govitecan	MTD (Ph I), ORR (Ph II)	Ongoing: Actively recruiting.	45

Safety and Tolerability Profile

The safety profile of Berzosertib has been extensively characterized in numerous clinical trials. While generally considered to have a manageable toxicity profile, its use is consistently associated with significant on-target adverse events, particularly when combined with cytotoxic chemotherapy.

Hematologic Toxicities (Myelosuppression)

Myelosuppression is the most common, clinically significant, and dose-limiting toxicity (DLT) associated with Berzosertib treatment.[20] This is a direct consequence of inhibiting ATR in the rapidly proliferating hematopoietic progenitor cells of the bone marrow. The incidence of Grade 3 or 4 hematologic adverse events is high across nearly all combination regimens studied.

• With Cisplatin and Veliparib: In a Phase I trial, the most common Grade 3/4 adverse events were myelosuppressive, including anemia (37.7%), thrombocytopenia (32.1%), leukopenia (24.5%), neutropenia (22.6%), and lymphopenia (20.8%).[35]
• With Irinotecan: A Phase I study reported Grade ≥3 neutrophil decrease (34%), lymphocyte decrease (30%), WBC decrease (28%), and anemia (20%).[33]
• With Cisplatin and Gemcitabine: In a randomized trial for urothelial cancer, the Berzosertib arm experienced significantly higher rates of Grade 3-4 adverse events compared to the control arm (91% vs. 66%), driven primarily by increased rates of thrombocytopenia (59% vs. 39%) and neutropenia (37% vs. 27%).[37]
• With Topotecan: In the NCI's SCLC trial, hematologic toxicities were nearly universal, with the most common Grade 3 or 4 events being lymphopenia (69.2%), thrombocytopenia (57.7%), and anemia (42.3%).[6]

The clinical consequence of this severe myelosuppression is significant. It frequently requires dose reductions, interruptions, or delays in treatment, not only for Berzosertib but also for the backbone chemotherapeutic agent. This was clearly demonstrated in the urothelial cancer trial, where patients receiving the Berzosertib combination received a significantly lower median dose of cisplatin, which may have compromised the regimen's overall efficacy.[35]

Non-Hematologic Adverse Events

Non-hematologic adverse events are also observed, though they are typically less frequent and of lower severity than the hematologic toxicities.

• Common Events: Grade ≥3 diarrhea (16%) and fatigue (8%) were noted in the irinotecan combination trial.[33] Nausea and vomiting are also common, though usually Grade 1 or 2.[6]
• Monotherapy Profile: The safety profile of Berzosertib as a single agent is considerably more favorable. A Phase I monotherapy study found it to be well tolerated, with the most common treatment-related adverse events being low-grade flushing (24%), nausea, pruritus, headache, and infusion-related reactions (12% each).[64] This stark difference highlights that the severe toxicity profile is an emergent property of combining ATR inhibition with cytotoxic chemotherapy.

The safety profile of Berzosertib can be viewed as a form of "mechanistic biomarker" that confirms its potent on-target activity. The consistent and severe myelosuppression is a double-edged sword: on one hand, it provides clear evidence of systemic, biologically effective ATR inhibition. On the other hand, it precisely defines the drug's primary therapeutic limitation. The challenge is not that the drug is ineffective, but rather that its mechanism works systemically on all rapidly dividing cells, both cancerous and healthy. This creates a direct, causal link between the desired antitumor effect and the dose-limiting side effect. This reframes the central clinical problem from simply managing side effects to the more complex task of creating a therapeutic window, which might require innovative strategies like intermittent dosing, development of tumor-targeted delivery systems, or co-administration of bone marrow-protective agents.

Preclinical Toxicology and Hazard Identification

Data from the European Chemicals Agency (ECHA) C&L Inventory, based on preclinical studies, provide warnings about potential long-term toxicities associated with Berzosertib.[10] These GHS classifications are consistent with a compound that targets a fundamental process of DNA maintenance and cell division:

• Germ Cell Mutagenicity (H341): Suspected of causing genetic defects.
• Reproductive Toxicity (H361fd): Suspected of damaging fertility and the unborn child.
• Specific Target Organ Toxicity, Repeated Exposure (H373): May cause damage to organs through prolonged or repeated exposure.

These preclinical findings underscore the need for careful long-term safety monitoring in patients who receive the drug.

Adverse Event (Grade ≥3)	+ Cisplatin / Veliparib 35	+ Irinotecan 33	+ Cisplatin / Gemcitabine 37	+ Topotecan 6
Anemia	37.7%	20%	N/A (not specified)	42.3%
Thrombocytopenia	32.1%	N/A	59% (vs 39% control)	57.7%
Neutropenia / Neutrophil ↓	22.6%	34%	37% (vs 27% control)	50.0%
Leukopenia / WBC ↓	24.5%	28%	N/A	N/A
Lymphopenia / Lymphocyte ↓	20.8%	30%	N/A	69.2%
Diarrhea	N/A	16%	N/A	N/A
Fatigue	N/A	8%	N/A	N/A

Strategic Analysis and Future Directions

Berzosertib's extensive clinical evaluation has provided invaluable lessons for the entire field of DDR inhibition. Its mixed results have clarified the path forward, emphasizing the need for precision medicine while highlighting the challenges inherent to this therapeutic class. A strategic analysis of its position in the competitive landscape, its core challenges, and its potential future reveals a complex but informative picture.

Comparative Landscape of ATR Inhibitors

Berzosertib was the first ATR inhibitor to enter the clinic, but it is no longer the only one. Several other agents are now in development, creating a competitive landscape.[22]

• Potency and Selectivity: Berzosertib is a highly potent inhibitor with a Ki​ of less than 0.3 nM.[20] Other clinical-stage inhibitors include ceralasertib (AZD6738), M4344 (VX-803), and BAY1895344. While direct comparisons are complex, one analysis of potency ranked several ATR inhibitors, placing Berzosertib below some newer agents like Camonsertib.[22]
• Route of Administration: Perhaps the most significant differentiator is the route of administration. Berzosertib is an intravenous agent. In contrast, many of its key competitors, including ceralasertib and Merck KGaA's own next-generation compound M1774, are orally bioavailable.[5] Oral administration offers substantial advantages in terms of patient convenience, reduced healthcare system burden, and the potential for more flexible or chronic dosing schedules, such as in a maintenance setting.

Challenges and the Imperative for Biomarkers

The clinical journey of Berzosertib has been defined by one overarching challenge: achieving a sufficiently wide therapeutic window.

• On-Target Toxicity: The primary obstacle is the on-target myelosuppression that results from inhibiting a pathway essential for healthy hematopoietic cells. This toxicity limits the dose of Berzosertib that can be safely combined with full-dose chemotherapy, as starkly demonstrated in the failed urothelial cancer trial.[37]
• The Failure of the Agnostic Approach: The discontinuation of the DDRiver SCLC 250 trial was a pivotal moment, proving that even in a tumor type with a strong theoretical rationale for ATR inhibition (high replication stress), an unselected patient population is unlikely to derive sufficient benefit to outweigh the risks.[5]
• The Mandate for Precision: The clear successes of Berzosertib have occurred exclusively in molecularly defined patient subgroups. This mandates that the future development of Berzosertib—and indeed all ATR inhibitors—must be guided by robust, validated predictive biomarkers. Candidate biomarkers that have shown the most promise in clinical studies include:
• DDR Gene Alterations: Loss-of-function mutations in ATM have provided the strongest and most consistent signal of sensitivity to ATR inhibition.[33] Alterations in other DDR genes like ARID1A, BRCA1/2, and CHK2 are also being actively investigated as potential predictors of response.[23]
• Replication Stress Signatures: The finding from the ovarian cancer trial that a genomic signature of "low replication stress" predicted benefit is intriguing and counterintuitive, suggesting a more complex interplay between DDR pathways than previously understood. Further research is needed to validate and understand this biomarker.[49]

The Path Forward: Rational Combinations and Strategic Pivots

The future of the Berzosertib program depends on its ability to adapt to these lessons. The strategy is now shifting toward smarter, more rational combinations in highly selected patient populations.

• Novel Combinations: The ongoing trials with lurbinectedin (NCT04802174) and the antibody-drug conjugate sacituzumab govitecan (NCT04826341) represent this new direction.[45] These trials are designed to test Berzosertib with novel DNA-damaging agents in populations enriched for DDR defects (e.g., HRD-positive, PARP inhibitor-resistant cancers), a more targeted approach than simply combining it with conventional platinum agents.
• Merck KGaA's Portfolio Strategy: The fact that Merck KGaA is simultaneously developing M1774, a next-generation oral ATR inhibitor, is strategically significant.[4] Berzosertib, as the first-in-class IV agent, has served a crucial role in de-risking the ATR target and providing invaluable proof-of-concept data. It is plausible that the company's long-term commercial strategy may prioritize the more convenient oral agent, while Berzosertib is reserved for niche indications or further exploratory studies to inform the broader DDR portfolio.

Conclusion

Berzosertib is a landmark molecule in the development of DNA Damage Response inhibitors. It has successfully validated ATR as a druggable and clinically relevant target in oncology, demonstrating that exploiting the principle of synthetic lethality can lead to profound and durable responses in some patients with hard-to-treat cancers.

However, its clinical development has also been a cautionary tale, illustrating the quintessential challenges of targeted therapy. Its potent, on-target mechanism is a double-edged sword, leading to dose-limiting myelosuppression that narrows the therapeutic window and complicates combination strategies. The divergent outcomes of its clinical trials—from the clear success in biomarker-selected, platinum-resistant ovarian cancer to the definitive failure in unselected small cell lung cancer—have delivered an unequivocal message: the future of ATR inhibition lies in precision oncology.

The ultimate clinical role of Berzosertib may be as a niche therapeutic for specific, molecularly defined patient populations, such as those with ATM-deficient tumors. Its greater and more enduring legacy, however, will be the foundational clinical and biological knowledge it has generated. The lessons learned from the successes and failures of Berzosertib have illuminated the path forward, paving the way for a new generation of more refined, biomarker-guided, and potentially oral ATR inhibitors that may one day become a standard of care.

Works cited

1. Berzosertib - Wikipedia, accessed September 15, 2025, https://en.wikipedia.org/wiki/Berzosertib
2. Berzosertib | CAS#1232416-25-9 | ATR Inhibitor - MedKoo Biosciences, accessed September 15, 2025, https://www.medkoo.com/products/4539
3. Merck KGaA, Darmstadt, Germany, Advances ATR Inhibitor ..., accessed September 15, 2025, https://www.emdgroup.com/en/news/berzosertib-cancer-cell.html
4. News Release Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways, accessed September 15, 2025, https://www.merckgroup.com/press-releases/2022/june/en/Oncology-development-update-EN.pdf
5. Merck Ends Lung Cancer Berzosertib Trial to Consider Future of ATR Inhibitor, accessed September 15, 2025, https://respiratory-therapy.com/disorders-diseases/cardiopulmonary-thoracic/lung-cancer/merck-kgaa-cuts-lung-cancer-trial-to-consider-future-of-atr-inhibitor/
6. 2021-04-12 EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer, accessed September 15, 2025, https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-advances-atr-inhibitor-berzosertib-in-small-cell-lung-cancer-12-04-2021.html
7. Berzosertib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 15, 2025, https://go.drugbank.com/drugs/DB11794
8. berzosertib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 15, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003
9. pubchem.ncbi.nlm.nih.gov, accessed September 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/59472121#:~:text=3%2D%5B3%2D%5B4,2%2Dpyrazinamine%20is%20a%20sulfonamide.
10. Berzosertib | C24H25N5O3S | CID 59472121 - PubChem, accessed September 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/59472121
11. Berzosertib by Merck for Solid Tumor: Likelihood of Approval - Pharmaceutical Technology, accessed September 15, 2025, https://www.pharmaceutical-technology.com/data-insights/berzosertib-merck-solid-tumor-likelihood-of-approval/
12. Search for an orphan drug - Orphanet, accessed September 15, 2025, https://www.orpha.net/en/drug
13. FDA and EMA Resources, Policies, and Programs Relevant for Drug Development for Rare Diseases and Conditions - NCBI, accessed September 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK609376/
14. Berzosertib - Orphanet, accessed September 15, 2025, https://www.orpha.net/en/drug/substance/604148?name=&mode=pat®ion=&status=all
15. Pipeline Moves: Merck KGaA's berzosertib progression shot in small-cell lung cancer reviewed after Phase II discontinued - Clinical Trials Arena, accessed September 15, 2025, https://www.clinicaltrialsarena.com/features/berzosertib-lung-cancer-trial-discontinued/
16. Development Programs in Oncology - Merck KGaA, Darmstadt, Germany, accessed September 15, 2025, https://www.emdgroup.com/en/news/development-projects-in-oncology-03-06-2022.html
17. Search Orphan Drug Designations and Approvals - accessdata.fda.gov, accessed September 15, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/
18. Search Orphan Drug Designations and Approvals - FDA, accessed September 15, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1047424
19. Definition of berzosertib - NCI Drug Dictionary - NCI, accessed September 15, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/berzosertib
20. Berzosertib – Knowledge and References – Taylor & Francis, accessed September 15, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Berzosertib/
21. Berzosertib. ATR kinase inhibitor, Treatment of solid tumors, accessed September 15, 2025, https://access.portico.org/Portico/show?viewFile=pdf&auId=pjbf78x71b8
22. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy | Request PDF - ResearchGate, accessed September 15, 2025, https://www.researchgate.net/publication/339506607_Discovery_of_ATR_kinase_inhibitor_berzosertib_VX-970_M6620_Clinical_candidate_for_cancer_therapy
23. Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in ..., accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7918546/
24. Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators - PMC, accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11338954/
25. ATR and Chk1 Suppress a Caspase-3–Dependent Apoptotic Response Following DNA Replication Stress | PLOS Genetics - Research journals, accessed September 15, 2025, https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1000324
26. Chemical strategies for development of ATR inhibitors | Expert Reviews in Molecular Medicine | Cambridge Core, accessed September 15, 2025, https://www.cambridge.org/core/journals/expert-reviews-in-molecular-medicine/article/chemical-strategies-for-development-of-atr-inhibitors/36616F34646E8793CD4B82091059D4F5
27. Berzosertib (VE-822) | ATR Inhibitor - Ambeed.com, accessed September 15, 2025, https://www.ambeed.com/products/berzosertib.html
28. Berzosertib (VE-822) | ATR Inhibitor - MedchemExpress.com, accessed September 15, 2025, https://www.medchemexpress.com/VE-822.html
29. en.wikipedia.org, accessed September 15, 2025, https://en.wikipedia.org/wiki/Berzosertib#:~:text=It%20acts%20as%20a%20potent,cycle%20checkpoints%20during%20cell%20division.
30. berzosertib - My Cancer Genome, accessed September 15, 2025, https://www.mycancergenome.org/content/drugs/berzosertib/
31. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer - PubMed Central, accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8991212/
32. SCLC Completed Phase 1 Trials for Berzosertib (DB11794) | DrugBank Online, accessed September 15, 2025, https://go.drugbank.com/indications/DBCOND0030108/clinical_trials/DB11794?phase=1&status=completed
33. NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors. - ASCO, accessed September 15, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT367032
34. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/37934325/
35. Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia ..., accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12278758/
36. Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors | JCO Precision Oncology - ASCO Publications, accessed September 15, 2025, https://ascopubs.org/doi/abs/10.1200/PO-25-00055
37. Addition of ATR Inhibitor Berzosertib to Cisplatin/Gemcitabine in Metastatic Urothelial Carcinoma - The ASCO Post, accessed September 15, 2025, https://ascopost.com/news/september-2021/addition-of-atr-inhibitor-berzosertib-to-cisplatingemcitabine-in-metastatic-urothelial-carcinoma/
38. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types - PMC - PubMed Central, accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7870753/
39. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/33145616/
40. (PDF) Microtracer‐Based Assessment of the Mass Balance ..., accessed September 15, 2025, https://www.researchgate.net/publication/392195894_Microtracer-Based_Assessment_of_the_Mass_Balance_Pharmacokinetics_and_Excretion_of_CBerzosertib_an_Intravenous_ATR_Inhibitor_in_Patients_With_Advanced_Solid_Tumors_A_Phase_1_Study
41. Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice, accessed September 15, 2025, https://www.researchgate.net/publication/380570268_Non-linear_IV_pharmacokinetics_of_the_ATR_inhibitor_berzosertib_M6620_in_mice
42. Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/40437704/
43. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3 ..., accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9351722/
44. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/34556535/
45. Clinical Trials Using Berzosertib - NCI, accessed September 15, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/berzosertib
46. NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | ClinicalTrials.gov, accessed September 15, 2025, https://clinicaltrials.gov/study/NCT04826341
47. Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers - NCI, accessed September 15, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-02549
48. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/38635934/
49. Randomized phase 2 study of gemcitabine with or without ATR ..., accessed September 15, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5512
50. Berzosertib shows promise in first clinical trial - The Cancer Letter, accessed September 15, 2025, https://cancerletter.com/clinical-roundup/20200619_7c/
51. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial - Mayo Clinic, accessed September 15, 2025, https://mayoclinic.elsevierpure.com/en/publications/berzosertib-plus-gemcitabine-versus-gemcitabine-alone-in-platinum
52. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses | JCO Precision Oncology - ASCO Publications, accessed September 15, 2025, https://ascopubs.org/doi/abs/10.1200/PO.23.00635
53. Study Details | NCT02487095 | Trial of Topotecan With VX-970 ..., accessed September 15, 2025, https://www.clinicaltrials.gov/study/NCT02487095
54. Therapeutic Targeting of ATR Yields Durable Regressions in High Replication Stress Tumors - dbGaP Study, accessed September 15, 2025, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002327.v1.p1
55. Clinical Trial: NCT02487095 - My Cancer Genome, accessed September 15, 2025, https://www.mycancergenome.org/content/clinical_trials/NCT02487095/
56. Drug combination leads to durable responses in patients with small cell lung cancer, accessed September 15, 2025, https://ccr.cancer.gov/news/article/drug-combination-leads-to-durable-responses-in-patients-with-small-cell-lung-cancer
57. News Release Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase, accessed September 15, 2025, https://www.merckgroup.com/press-releases/2021/apr/en/Berzosertib-Cancer-Cell-Ph-II-NCI-SCLC-EN.pdf
58. Home | ClinicalTrials.gov, accessed September 15, 2025, https://clinicaltrials.gov/study/NCT02487095
59. Study Details | NCT04768296 | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | ClinicalTrials.gov, accessed September 15, 2025, https://clinicaltrials.gov/study/NCT04768296?term=NCT02487095%20NCT04768296%20NCT04802174%20NCT04826341&rank=3
60. After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor - Fierce Biotech, accessed September 15, 2025, https://www.fiercebiotech.com/biotech/after-deeming-success-unlikely-merck-kgaa-cuts-lung-cancer-trial-consider-future-atr
61. Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival - News-Medical, accessed September 15, 2025, https://www.news-medical.net/news/20210827/Adding-berzosertib-to-standard-treatment-for-metastatic-urothelial-cancer-does-not-extend-patient-survival.aspx
62. NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors. - ASCO Publications, accessed September 15, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3012
63. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/34040174/
64. Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors, accessed September 15, 2025, https://ascopost.com/news/july-2020/phase-i-trial-of-berzosertib-alone-or-combined-with-carboplatin-in-advanced-solid-tumors/
65. Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial - PMC, accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10524218/
66. Targeting ATR in patients with cancer - MD Anderson Cancer Center, accessed September 15, 2025, https://mdanderson.elsevierpure.com/en/publications/targeting-atr-in-patients-with-cancer
67. Full article: Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics - Taylor & Francis Online, accessed September 15, 2025, https://www.tandfonline.com/doi/full/10.1080/14756366.2025.2489720
68. Prospects for the Use of ATR Inhibitors to Treat Cancer - MDPI, accessed September 15, 2025, https://www.mdpi.com/1424-8247/3/5/1311
69. A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors., accessed September 15, 2025, https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS3153
70. Progress towards a clinically-successful ATR inhibitor for cancer therapy - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/34909652/